Stage IV pancreatic cancer is a death sentence for most people.
The five-year survival rate sits at three percent. Not fifteen. Not twenty. Three.
That has been the grim reality for years. Shubham Pant calls the prognosis “historically poor,” which is a polite way of saying patients are often running out of time while the disease spreads.
Then comes daraxonrasib.
It’s generating a fuss in the oncology world after a recent study showed it nearly doubles how long patients live. Ignacio Garrido Laguna admits he’s never seen results this caliber. He’s not used to being surprised.
The drug hasn’t hit shelves yet. The FDA hasn’t signed off. But oncologists are watching closely, waiting for the green light, while trying to get the medication into their patients’ hands through special access programs.
What the data actually shows
Five hundred patients participated in the phase 3 trial.
They were spread across North America, Europe, Asia. All had metastatic pancreatic ductal adenocARCinoma (mPDAC). All had already tried chemotherapy and failed. Most could still walk around and do basic things, which kept them eligible for the study.
Here is the kicker.
After roughly 8.5 months of observation, the daraxonrasib group lived an average of 13.2 months.
The chemotherapy group? Six to seven months. Depending on tumor type, the gap might narrow, but the drug group still lived about twice as long.
Quality of life matters, too.
Chemotherapy wrecks bodies. Daraxonrasib didn’t cause nearly as many severe side effects. Only 1.2% of people on the pill stopped taking it because of the effects. Over 11% of those on chemo had to quit. It’s a harder road when the treatment kills you as surely as the disease does.
How it works differently
This isn’t chemo in disguise.
Daraxonrasib is a pill. You take it. It goes to work on a protein called KRAS.
“It has a very novel mechanism action.”
— Ignacio Garrido Laguna
Most pancreatic cancers—more than 90% of them, according to Peter Hosein—run on a mutation in that KRAS protein. It’s the engine. The fuel. The problem.
Previous drugs only targeted a specific subtype, G12C. That covers a small fraction of patients. Daraxonrasib is different. It targets KRAS itself. Regardless of the subtype.
Dr. Hosein calls it a “panRAS” inhibitor. The first to prove its worth in a large trial. It turns the protein off. Stops growth. Whether you have the common mutation or a rarer variant.
Not a cure. Just longer life.
Don’t get too ahead of yourself.
This isn’t the holy grail. Pancreatic cancer gets caught late. Usually too late for surgery. Usually when it’s already everywhere.
“We don’t have tools to make early diagnosis,” Dr. Laguna says bluntly.
Daraxonrasib extends life, sure. It blocks the growth driver for a while. But cancer is clever. It adapts. Eventually, the cells figure out a way around the blockade. The drug stops working.
Brandon Huffman warns against calling this a victory lap. “Eventually,” he notes, “lives will be shortened as a consequence of resistance.”
It’s a bridge. Not the other side of the river.
Getting access now
You can’t just order this from Amazon.
It’s still experimental. Unapproved by the FDA.
Revolution Medicines has an expanded access program, though. Any oncologist in the U.S. can apply if they have eligible patients. It’s messy, it’s bureaucratic, but it exists.
If you or someone you know has this diagnosis, talk to the oncologist. Ask about it.
The wait is long. The outcome is uncertain.
But three percent isn’t thirteen. Not yet, at least.
